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ABSTRACT 
We report on a patient with severe and fixed lichenoid drug-reaction.  She did not respond to 2 months treatment with high-dose 
corticosteroids.  Hence, Rituximab was given.  One month later, her lesions improved and remained stable for 14 months of fol low up.     
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A number of uncommon, clinically diverse and poorly 
understood inflammatory skin diseases are linked by the 
presence of a set of histopathological elements that have 
traditionally been referred to as the "lichenoid tissue 
reaction/interface dermatitis" (LTR/IFD) 1. The prototypic 
skin disease in this category is lichen planus. However, the 
LTR/IFD can also be seen in skin disorders associated with 
systemic illnesses (lupus erythematosus, HIV, 
dermatomyositis), and the skin changes of potentially fatal 
disorders such as graft-versus-host disease, Stevens-Johnson 
syndrome, and toxic epidermal necrolysis 2.  In 1998, 
LTR/IFD has been described following drug exposure and 
has been labeled as lichenoid drug-reaction (LDR) 3.  
Fortunately, most LDR disappear after drug withdrawal or 
following a short course of Corticosteroids 4.  However, our 
patient had developed severe form of LDR that persisted for 
months following drug discontinuation and did not improve 
with Corticosteroids.  Based on its mode of action; Rituximab 
was used and cured our patient.    
THE CASE 
The patient is a 73-year-old Kuwaiti woman.  She had 
diabetes mellitus and hypertension.  She had received a 5-
days course of Ciprofloxacin for treatment of urinary tract 
infection.  Few days later; she presented with several 
erythematous well limited, patches, of varying size, 
associated to multiples keratotic erythematous papules with 
erosions covered by hemorrhagic crusts, dispersed to the 
trunk and limbs with adherent whitish scales.  Despite 
discontinuation of the drug and a 2 weeks course of 
Prednisone 1 mg/kg/day; she did not improve.  On her 
initial examination; she was conscious and oriented X3.  She 
was afebrile and systemic examination did not show 
abnormality.  All her body was covered with multiple, well-
circumscribed hyperkeratotic erythemtous skin lesions 
covered by hemorrhagic crusts with adherent whitish scales 
(Fig. 1A).  Laboratory investigations; showed normal 
complete blood counts, urine routine and microscopy, renal 
and liver profiles as well as serum complements (C3 & C4), 
IgA level and protein electrophoresis.  ANA, anti-ds DNA, 
ANCA, anti-GBM-antibodies, RA, hepatitis B surface antigen 
and anti-HCV antibodies were negative. 
Chest x-ray, abdominal and pelvic ultrasounds were normal.  
She was treated with Rituximab 1 g followed by 1 g 2 weeks 
later.  Over the next month; all her keratotic skin lesions had 
disappeared and she was left only with areas of 
hyperpigmentation (Fig .1B).  
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Figure 1 Lichenoid fixed drug reaction before (A) and after (B) treatment with Rituximab 
 
DISCUSSION 
Lichenoid drug eruptions have been reported with ACE 
inhibitors, Beta blockers, Amlodopine, Diliazem, Gold salts, 
Interferon alpha-2b, Immunoglobulins, Levamisole, 
Methyldopa, NSAIDs, PPI, Penicillamine, Simvostatins, 
Carbamazepine, Chloropromazine, Quinine, Tetracycline, 
Thiazide and anti-tuberculous drugs 2.  Ciprofloxacin is a 
quinolone antibiotic, which is widely used to treat gram 
positive and gram negative organisms as well as the 
anerobes in different parts of the body 5. Multiple cutaneous 
reactions to the drug have been reported yet fixed and 
persistent lichenoid reactions are rare 4.  Clinically, LED is 
characterized by an extensive symmetric eruption of flat-
topped violaceous plaques involving the trunk and 
extremities. Lesions of LDE are, violaceous papules and 
plaques, often larger in size, less monomorphic and more 
prone to be eczematous and associated with desquamation 
in contrast to that of lichen planus. They often spare the 
nails, oral and genital mucosae. Also, the absence of 
Wickham’s striae, photodistribution and a temporal 
association with drug intake help to differentiate the two 6. 
Lichenoid drug eruptions usually occur with a latent period 
of few weeks to several months 4.  Histologically, all the 
features of lichen planus can be seen in lichenoid drug 
eruptions, but Clues to the drug-induced etiology include 
epidermal parakeratosis, absence of wedge-shaped 
hypergranulosis, transepidermal necrotic keratinocytes, 
deeper mid-dermal perivascular and peri- adnexal infiltrates, 
and the presence of eosinophils 7.  Our patient exhibited 5 
unique features viz. (a) an acute onset after drug use (b) 
lichenoid features (c) persistent severe lesions (d) 
refractoriness even to systemic Corticosteroid-therapy, and 
(e) long-lasting remission after Rituximab treatment.  To our 
knowledge, the pathogenesis of lichenoid drug eruptions is a 
cytotoxic T‐cell mediated autoimmune damage to basal 
keratinocytes that are altered by the drug. The drug acts as 
hapten, binding to keratino/melanocytes producing an 
antibody-dependent suppressor/cytotoxic T-cell 
lymphocytes attack of the drug-altered epidermal cells 
leading to the eruption 8.  At the same time, cutaneous 
memory T-lymphocytes is recruited and amplify the allergic 
reaction in future exposure 9.  Moreover, amplification of 
such pathway involve the actions of plasmacytoid dendritic 
cell-derived IFN-alpha 8.  Resolution of the rash occurs once 
these altered keratinocytes are cleared 10.   Those were the 
basis of the use Rituximab in our patient.  The drug is a 
chimeric human/mouse monoclonal antibody that was 
approved in USA since 1997 for treatment of non-Hodgkin 
lymphoma and recently for severe rheumatoid arthritis and 
glomerulopathy 11.  The drug binds to CD20 antigen 
expressed on normal differentiated B-lymphocytes and pre-
B-cells.  Unlike other murine monoclonal antibodies to CD20, 
R persists in the circulation for long- periods, rarely 
generates human anti-mouse antibodies and interacts with 
human effector cells including T-lymphocytes.  The latter is 
though inhibition of antigen-presenting to the T-cells 12, 13.  
The benifical effect of R is via suppression of antigen-
presentation followed by inhibition of T-cell recruitment, 
blockage of the amplification pathway of IFN-alpha and 
finally its long-term effect by suppression B-memory cell 
expansion 14. 
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